BeOne Medicines director exercises options and sells ADS stake

BeOne Medicines Ltd. director reports option exercise and ADS sales.

Rhea-AI Filing Summary

BeOne Medicines Ltd. director reports option exercise and ADS sales. On 11/26/2025, the reporting director exercised a share option covering 34,151 ordinary shares at an exercise price of $12.23 per share. Each American Depositary Share (ADS) represents 13 ordinary shares, so the exercise resulted in 2,627 ADS at a reported price of $159.03 per ADS. On the same date, the director sold 1,823 ADS at a weighted average price of $340.2004 and 804 ADS at a weighted average price of $342.474, leaving 0 ADS beneficially owned after the transactions. Following these activities, the director reported beneficial ownership of 57,226 ordinary shares held directly.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Sanders Corazon (Corsee) D.

Role Director

Sold 2,627 shs ($896K)

Approx. gross sale proceeds $896K

Approx. exercise cost $418K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	34,151	$0.00	$0.00
Exercise	American Depositary Shares	2,627	$159.03	$418K
Sale	American Depositary Shares	1,823	$340.2004	$620K
Sale	American Depositary Shares	804	$342.474	$275K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 0 contracts (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 57,226 shares (Direct)

Footnotes (5)

1. F1. Each American Depositary Share represents 13 Ordinary Shares.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
4. F4. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
5. F5. The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BeOne Medicines (ONC) disclose in this Form 4?

The filing reports that a director of BeOne Medicines Ltd. exercised options for 34,151 ordinary shares on 11/26/2025 and then sold the related American Depositary Shares (ADS) the same day.

How many BeOne Medicines (ONC) shares were involved in the option exercise?

The director exercised a share option covering 34,151 ordinary shares at an exercise price of $12.23 per share.

At what prices did the BeOne Medicines (ONC) director sell ADS?

The director sold 1,823 ADS at a weighted average price of $340.2004 and 804 ADS at a weighted average price of $342.474, with both sets of sales occurring on 11/26/2025.

How do BeOne Medicines (ONC) ADS relate to ordinary shares?

Each American Depositary Share of BeOne Medicines represents 13 ordinary shares, as stated in the explanation of responses.

What is the BeOne Medicines (ONC) director’s ownership after these transactions?

After the reported transactions, the director reported beneficial ownership of 57,226 ordinary shares held directly and 0 ADS and 0 options related to this grant.

What was the director’s role and filing status in the BeOne Medicines (ONC) Form 4?

The reporting person is identified as a director of BeOne Medicines Ltd., and the Form 4 was filed by one reporting person on an individual basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/01/2025 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								57,226	D
American Depositary Shares(1)	11/26/2025		M		2,627	A	$159.03	2,627	D
American Depositary Shares(1)	11/26/2025		S		1,823	D	$340.2004(2)	804	D
American Depositary Shares(1)	11/26/2025		S		804	D	$342.474(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$12.23(4)	11/26/2025		M			34,151	(5)	06/04/2034	Ordinary Shares	34,151	$0	0	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

4. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

5. The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.